Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Santaris

This page shows the latest Santaris news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

  • Chugai soars on Roche buyout rumours Chugai soars on Roche buyout rumours

    Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing

  • Roche pays $450m for 'gene-silencing' firm Santaris Pharma Roche pays $450m for 'gene-silencing' firm Santaris Pharma

    Roche's return to the field of RNAi research looks to be complete, following its $450m deal to acquire Denmark's Santaris Pharma. ... The deal is expected to close later this month, when Santaris' Danish operations will become the Roche Innovation Center

  • Shire extends rare genetic disease alliance

    Agrees option with Santaris to nominate additional discovery targets. Shire has expanded its rare genetic disease alliance with Danish biopharmaceutical company Santaris. ... The Danish clinical stage biopharmaceutical company's president and CEO Henrik

  • RNA interference rebirth RNA interference rebirth

    ALN-RSV01. Alnylam. RSV.  respiratory syncytial virus infection. IIb. miravirsen (SPC3649). Santaris Pharma. ... I. EZN-3042. Santaris Pharma. Survivin. cancer. I. EZN-2968. Santaris Pharma. HIF-1a.

  • Creative partnerships

    In January, Pfizer extended an existing collaboration with Santaris ($614m) for the 'locked nucleic acid' (LNA) technology for gene-silencing RNA technology. ... Preclinical. 632. Santaris Pharma/Pfizer. Expansion of Locked Nucleic Acid Drug platform

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics.

  • Pharma deals during August 2014 Pharma deals during August 2014

    August also saw Roche's pRED group acquire Santaris Pharma for $450m - $250m upfront and $200m contingent on predetermined research milestones. ... Clearly it has not taken Roche long to be convinced of these claims given its $10m discovery alliance with

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Santaris/Roche. Discovery and development. Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform.

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    199. Velcera/ Perrigo Company. Acquisition. Pet health products. 160. Santaris Pharma/ BMS.

  • Pharma deals during April 2013 Pharma deals during April 2013

    Platform technologies. Of the 11 large pharma deals announced in April,  8 involve platform technologies. In addition to those already mentioned are: Ambrx / Astellas; Isis/ Roche; Ra/ Merck; Santaris/ Bristol-Myers ... Santaris/ BMS. April also saw

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Quick links

Infographics

Multimedia